
USPH Stock Forecast & Price Target
USPH Analyst Ratings
Bulls say
US Physical Therapy Inc. is experiencing robust growth, particularly in its industrial injury prevention business, which has shown exceptional momentum in recent quarters. The company's financial guidance indicates an increase in adjusted EBITDA expectations for FY/25, now projected between $93 million to $97 million, reflecting an approximate 8.6% growth compared to the previous year. Additionally, the anticipated growth rates of 17.1% and 10.0% in different revenue segments suggest strong operational performance and a positive outlook for the company's financial trajectory.
Bears say
US Physical Therapy Inc. faces ongoing challenges due to its reliance on managed care programs and Medicare, which may affect its pricing power moving forward despite the anticipated absence of pricing headwinds in 2026. The company's revenue generation primarily stems from its Physical therapy operations segment, which is susceptible to fluctuations in reimbursement rates from commercial health insurance and government programs, raising concerns about revenue stability. Additionally, the broader economic climate and potential regulatory changes within the healthcare sector could further impact the company's financial performance and future growth prospects.
This aggregate rating is based on analysts' research of U.S. Physical Therapy and is not a guaranteed prediction by Public.com or investment advice.
USPH Analyst Forecast & Price Prediction
Start investing in USPH
Order type
Buy in
Order amount
Est. shares
0 shares